Heartflow, Inc. · NASDAQ:HTFL
Heartflow — Longview Acquisition Corp. II — SPAC Merger (October 2021)
29 slides from Heartflow's SPAC merger presentation, Oct 7, 2021
Slide 1: Investor Presentation October 2021
Investor Presentation October 2021
Slide 2: Disclaimer
Disclaimer 2 Disclaimer This presentation is for information purposes only to assist interested parties in making their own evaluation with respect t o t he proposed business combination (the “Business Combination”) between HeartFlow Holding, Inc. (“HeartFlow”) and Longview Acquisition Corp. II (“Lo
Slide 3: Disclaimer (continued)
Disclaimer (continued) 3 Industry and Market Data In this Presentation, Longview and HeartFlow rely on and refer to certain information and statistics obtained from third - party s ources which they believe to be reliable. Neither Longview nor HeartFlow has independently verified the accuracy or com
Slide 4: Transaction Overview
• Longview Acquisition Corp. II (“Longview II”) is a Special Purpose Acquisition Corporation (“SPAC”) brought public as an affiliate of Glenview Capital Management • Initially capitalized with $690 million in cash in trust in March 2021 trading under the ticker LGV • Glenview Capital was founded in
Slide 5: Transaction Overview
Transaction Overview Sources Equity to HeartFlow Stockholders $2,150.0 Longview Cash Held in Trust 1 690.0 Pre - Closing Return of Capital 1,2 (91.0) Total Sources 2 $2,749.0 Uses Equity to HeartFlow Stockholders $2,150.0 Cash to Balance Sheet 1,2 347.6 Cash for Secondary Purchases 110.0 Debt Retire
Slide 6: Driven by a Mission to Improve Cardiovascular Care
Driven by a Mission to Improve Cardiovascular Care for Patients, Physicians, Providers and Payers 6 1 2
Slide 7: Addressing the Number One Cause of Death and Largest Component of Chronic Health Spend
Addressing the Number One Cause of Death and Largest Component of Chronic Health Spend Source: CDC Division for Heart Disease and Stroke Prevention, 2019; American Heart Association, 2017; Yelin et. al. 7 1 out of every 3 deaths Cardiovascular Disease Costs Will Exceed $1 Trillion by 2035, Warns the
Slide 8: The Status Quo Heart Disease Care Pathway Is Suboptimal
The “Status Quo” Heart Disease Care Pathway Dominated by Echo & Nuclear Stress Testing is Suboptimal 8 Stress Echocardiography SPECT & PET Nuclear Scans Treadmill ECG Risk Assessment Non - invasive Testing 10M non - invasive tests in the US alone every year UNDETECTED DISEASE 20 - 30% FALSE NEGATIVE
Slide 9: The HeartFlow Heart Disease Pathway Enhances Patient Experience, Outcomes and Cost Savings
The HeartFlow Heart Disease Pathway Enhances the Patient Experience, Improves Outcomes and Delivers Cost Savings IDENTIFY DISEASE <1% LIKELIHOOD of missing disease 3 HIGHER ACCURACY 1 83% REDUCTION in unnecessary invasive angiograms 2 $2.7B annual cost - savings delivered to CMS through reduction of
Slide 10: Over a Decade Solving Technical, Business and Regulatory Challenges
2017 Commercial coverage began CMS engagement initiated Dec: Initiation of select coverage policies HeartFlow Has Spent Over a Decade Solving the Technical, Business and Regulatory Challenges Necessary to Unlock All Barriers to Adoption 2010 HeartFlow founded 2011 CE Mark obtained 2016 Japan PMDA Ap
Slide 11: Delivering Precise, Personalized and Enhanced Care Decisions for Patients
11 Delivering Precise, Personalized and Enhanced Care Decisions for Patients Assess Monitor Diagnose Plan Treat Assess Diagnose Plan Monitor Treat 5 1 2 3 4 • The historical path to diagnosing CAD is unclear, unreliable, insufficient and ineffective • Patients and staff benefit from a "one stop, clo
Slide 12: Revolutionary Precision Heart Care Technology
Treatment Planning Plaque 1 CTA - based Fractional Flow Reserve (FFR CT ) & Myocardial Blood Flow 2 12 HeartFlow Developed and Introduced a Revolutionary Precision “Heart Care” Technology that Disrupts the Status Quo HeartFlow’s product suite leverages and builds upon a foundational technology platf
Slide 13: Empowering Physicians with an AI-enabled, Cloud-based Enterprise Software Suite
• AI - powered modeling of all coronary arteries • H ighest diagnostic accuracy driven by big data analytics • Compliant cloud computing to protect sensitive data • Secure bi - directional data transmission to / from hospital IT systems ADVANCED TECH • Helps explain symptoms, providing peace - of -
Slide 14: AGE: 68. SEX: MALE HISTORY: ASYMPTOMATIC, FAMILY HISTORY OF HEART DISEASE * Currently in
14 14 AGE: 68. SEX: MALE HISTORY: ASYMPTOMATIC, FAMILY HISTORY OF HEART DISEASE * Currently in development and not available for clinical use. AGE: 60 SEX: MALE HISTORY: SYMPTOMATIC, FAMILY HISTORY OF HEART DISEASE * Currently in development and not available for clinical use.
Slide 15: Providing Significant Clinical Evidence
≫ 16 company - sponsored clinical trials and registries addressing accuracy and outcomes ≫ 100+ investigator - initiated studies ≫ 425+ peer - reviewed publications , including JAMA, JACC, Circulation, American Journal of Cardiology, European Heart Journal and Heart ≫ Studied in >10,000 patients ≫ D
Slide 16: Unmatched IP Portfolio Built on Years of Innovation
16 Unmatched IP Portfolio Built on 25 Years of Innovation 400+ Issued patents worldwide 2 Petabytes+ of Coronary I maging D ata 15 Million+ Annotated CT Images Leveraging a Strong Intellectual Property Portfolio HeartFlow’s differentiated IP portfolio provides a powerful competitive advantage, while
Slide 17: System-Wide Adoption
17 System - Wide Adoption 1. Top 50 Heart Hospitals as designated by US News and World Report 2. Includes 71% coverage with local coverage determinations and 29% on a case - by - case basis 80% of the T op 50 Heart Hospitals 1 in the US H ave Adopted HeartFlow Large healthcare systems have initiated
Slide 18: Predictable and Attractive SaaS Model
Fee - per - analysis for delivery of FFR CT and Plaque 1 18 • FFR CT • Plaque Comprehensive engagement with customer sites drives land, retain, and expand strategy Revenue Model Subscription provides access to bundle of advanced product features Products • PreRead • Myocardial Insights • Planner Pro
Slide 19: Robust Software Pipeline to Fuel a Significant TAM
19 Augmented by a Robust Software Pipeline to Fuel a Significant TAM HeartFlow is developing a comprehensive, integrated cloud - based heart care technology product suite to help physicians make more optimal cardiovascular care decisions FFR CT Planner PreRead Myocardial Insights Plaque Analysis Ana
Slide 20: From a Fraction of a Fraction to a Majority of a Majority
20 Augmented by a Robust Software Pipeline to Fuel a Significant TAM From a fraction of a fraction to a majority of a majority • Over the coming 15 years, we envision HeartFlow moving from a small minority of coronary CTA scans to being attached to the v ast majority • Additionally, over the same pe
Slide 21: Clear Development Path to Grow TAM from $10B to $50B+
21 Asymptomatic / Preventative Today Near Term Medium Term Long Term FFR CT Fee Per Analysis $10.1B Symptomatic Total: $10.1B Total: $10.8B Total: $17.9B Total: $49.7B Augmented by a Robust Software Pipeline to Fuel a Significant TAM HeartFlow has a clear projected development path to grow TAM from
Slide 22: Fueling a Compelling High Growth Outlook
● Anticipated ACC/AHA guidelines prioritizing CTA - FFR CT pathway ● CMS reimbursement changes enabling PFS market access, OPPS upside, national payment rate ● Enhanced sales strategy driven by 85% increase in US Sales Force and intelligent provider prioritization ● A robust pipeline of “HeartFlow U
Slide 23: Near-Term Growth Drivers: Industry Tailwinds
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guidelines for the Evaluation and Diagnosis of Chest Pain A Report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines Fueling a Compelling High Growth Outlook: Near - Term Growth Drivers Anticipated
Slide 24: Near-Term Growth Drivers: Expanded US Sales Footprint
Fueling a Compelling High Growth Outlook: Near - Term Growth Drivers Expanded US sales footprint to capitalize on industry tailwinds and new customer offerings 24 + • A standardized workflow where all coronary CTAs are sent to HeartFlow (to facilitate efficient and timely reporting of ordered analys
Slide 25: Fueling a Compelling High Growth Outlook: Revenue and Gross Margin
$23 $36 - $42 $92 $205 $345 $525 $0 $200 $400 $600 2020A 2021E 2022E 2023E 2024E 2025E 25 Fueling a Compelling High Growth Outlook Revenue ($ millions) 33% ~49+% ~69% ~78% ~82% ~85% 0% 20% 40% 60% 80% 100% 2020A 2021E 2022E 2023E 2024E 2025E Gross Margin 2021 - 2025 Plan Management believes that Hea
Slide 26: Led by a Strong Team
Charles A. Taylor, Ph.D.* Founder, Chief Technology Officer Stanford University, GE John Stevens, M.D.* President & CEO, Co - founder Heartport , Amp Resources, Stanford University Nicky Espinosa General Counsel, Chief Ethics and Compliance Officer Brobeck , Phleger & Harrison, Illumina, Intuitive S
Slide 27: Fortified by Experienced Investment Partners
Fortified by Experienced Investment Partners 27 Existing HeartFlow Investor Base
Slide 28: Enabling Access to Optimized Care for All Patient Populations
Enabling Access to Optimized Care for All Patient Populations Unlock & Penetrate Significant TAM Expand & Enhance Access to Care Improve Quality of Care Reduce Cost Improve Diagnostic Accuracy Improve Patient Experience Disruptive, Best - in - class Non - invasive Precision Heart Care Robust Intelle
Slide 29: Thank You!
Tnank You! O HeartFlow’
Longview Acquisition Corp. II — SPAC Merger (October 2021) on 6ix